Viatris Settles EpiPen Antitrust Litigation for $264 Million

Viatris, the drugmaker beforehand often called Mylan, introduced on Monday that it had agreed to pay $264 million to settle a class-action lawsuit that alleged the corporate was concerned in an unlawful scheme to monopolize the marketplace for epinephrine auto-injector units often called EpiPens, that are used to deal with extreme allergic reactions. The proposed